Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
   Rule 13d-1(b)
   Rule 13d-1(c)
   Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G




Comment for Type of Reporting Person:   (1) The figures in Items 6, 8, and 9 represent common stock, par value $0.001 ("Common Stock") of Quince Therapeutics, Inc. (the "Issuer"), held by Ikarian Healthcare Master Fund, L.P., a Cayman Islands exempted limited partnership (the "Fund"), and certain separately managed accounts. See Item 2 for more information. (2) The figure in Item 11 is based upon 1,017,063 shares of Common Stock of the Issuer outstanding as of July 29, 2026, as disclosed in the Issuer's Schedule 14A filed with the U.S. Securities and Exchange Commission (the "SEC") on July 31, 2026.


SCHEDULE 13G




Comment for Type of Reporting Person:   (1) The figures in Items 6, 8, and 9 represent Common Stock of the Issuer held by the Fund and certain separately managed accounts. See Item 2 for more information. (2) The figure in Item 11 is based upon 1,017,063 shares of Common Stock of the Issuer outstanding as of July 29, 2026, as disclosed in the Issuer's Schedule 14A filed with the SEC on July 31, 2026.


SCHEDULE 13G



 
Ikarian Capital, LLC
 
Signature:/s/ Neil Shahrestani
Name/Title:Neil Shahrestani, Sole Manager
Date:08/14/2026
 
Neil Shahrestani
 
Signature:/s/ Neil Shahrestani
Name/Title:Neil Shahrestani
Date:08/14/2026
Exhibit Information

Exhibit 99.1 Joint Filing Agreement (filed herewith).


ATTACHMENTS / EXHIBITS

ATTACHMENTS / EXHIBITS

EX-99.1